Determining the effect of ranolazine on blood LDL levels 2 months after acute myocardial infarction

Evaluation of the effect of ranolazine on blood LDL level changes two months after ST-elevation myocardial infarction(STEMI )

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251211068286N1

Enrollment

116

Registered

2025-12-24

Start date

2026-01-21

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group:They receive the drug Ranolazine 500 every 12 hours (manufactured by Actoverco, Alborz, Iran) when they visit the emergency room for 8 weeks. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients referred to BuAli Hospital with complaints of chest pain and possible MI

Exclusion criteria

Exclusion criteria: End-stage lung or liver disease GFR < 60 Use of ranolazine in the past 3 months Allergy to prescribed medications Cardiogenic shock Qt over 500 Use of common medications that cause changes in the QT interval

Design outcomes

Primary

Measure	Time frame
Blood LDL levels. Timepoint: 2 months after acute myocardial infarction. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactToba Jafari

Qazvin University of Medical Sciences

tobajafari@yahoo.com+98 28 3332 6034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026